Cargando…
Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada
The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327419/ https://www.ncbi.nlm.nih.gov/pubmed/32637472 http://dx.doi.org/10.1016/j.dib.2020.105842 |
_version_ | 1783552540463333376 |
---|---|
author | Fadaleh, Sarah Abu Shkrobot, Jody Makhinova, Tatiana Eurich, Dean Sadowski, Cheryl A. |
author_facet | Fadaleh, Sarah Abu Shkrobot, Jody Makhinova, Tatiana Eurich, Dean Sadowski, Cheryl A. |
author_sort | Fadaleh, Sarah Abu |
collection | PubMed |
description | The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different medications commonly used, according to Canadian Institute for Health Information. Eight different deprescribing scenarios were created, based on recommendations from Beers Criteria and the Canadian Deprescribing Network, for the purpose of comparing the cost difference before and after each intervention on pharmacies, patients, and governments. Scenarios included: (1) Stopping an over the counter medication; (2) Discontinuation of a medication; (3) Slow taper of a potentially inappropriate medication; (4) Rapid taper of a potentially inappropriate medication; (5) Switching to safer medication; (6) Dose reduction; (7) Switching to a lower cost medication; (8) Changing from combination to a single medication. The data presented are related to the article entitled “Financial advantage or barrier when deprescribing for seniors: A case based analysis” [1] |
format | Online Article Text |
id | pubmed-7327419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-73274192020-07-06 Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada Fadaleh, Sarah Abu Shkrobot, Jody Makhinova, Tatiana Eurich, Dean Sadowski, Cheryl A. Data Brief Pharmacology, Toxicology and Pharmaceutical Science The dataset covers the equations and procedure used for the estimation of an older adult's total annual medication costs, across Canadian provinces and territories; detailed to report pharmacy margin, government share, and patient share. We presented a case of an older adult using 10 different medications commonly used, according to Canadian Institute for Health Information. Eight different deprescribing scenarios were created, based on recommendations from Beers Criteria and the Canadian Deprescribing Network, for the purpose of comparing the cost difference before and after each intervention on pharmacies, patients, and governments. Scenarios included: (1) Stopping an over the counter medication; (2) Discontinuation of a medication; (3) Slow taper of a potentially inappropriate medication; (4) Rapid taper of a potentially inappropriate medication; (5) Switching to safer medication; (6) Dose reduction; (7) Switching to a lower cost medication; (8) Changing from combination to a single medication. The data presented are related to the article entitled “Financial advantage or barrier when deprescribing for seniors: A case based analysis” [1] Elsevier 2020-06-08 /pmc/articles/PMC7327419/ /pubmed/32637472 http://dx.doi.org/10.1016/j.dib.2020.105842 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Pharmacology, Toxicology and Pharmaceutical Science Fadaleh, Sarah Abu Shkrobot, Jody Makhinova, Tatiana Eurich, Dean Sadowski, Cheryl A. Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada |
title | Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada |
title_full | Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada |
title_fullStr | Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada |
title_full_unstemmed | Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada |
title_short | Dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in Canada |
title_sort | dataset on cost-analysis of medication deprescribing scenarios for older adult coverage under public drug benefit programs in canada |
topic | Pharmacology, Toxicology and Pharmaceutical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327419/ https://www.ncbi.nlm.nih.gov/pubmed/32637472 http://dx.doi.org/10.1016/j.dib.2020.105842 |
work_keys_str_mv | AT fadalehsarahabu datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada AT shkrobotjody datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada AT makhinovatatiana datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada AT eurichdean datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada AT sadowskicheryla datasetoncostanalysisofmedicationdeprescribingscenariosforolderadultcoverageunderpublicdrugbenefitprogramsincanada |